Importantly, analysis of clinical datasets revealed that high AXL expression is significantly associated with worse distant-metastasis-free survival (DMFS) in both breast cancer and TNBC, further supporting the clinical relevance of AXL as both a prognostic biomarker and a therapeutic target. The gene discussed is AXL; the disease is breast carcinoma.